Breaking News

0 332
Nabriva Therapeutics PLC – ADR NBRV Stock News

Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV) is off to an incredibly strong start in the early hours of today’s trading session and for good reason. The company released clinical data with regard to a key trial that proved to be overwhelmingly positive. Of course, this led to excitement among investors who are pushing the stock toward the top. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. At the moment (10:06), NBRV is trading at $12.40 per share after a gain of $5.54 per share or 80.83% thus far today.





NBRV Gains On Strong Clinical Data

As mentioned above, NBRV is having an overwhelmingly strong start to the trading session this morning after the company announced positive top-line data from a key clinical trial. The trial, known as LEAP 1 was designed to evaluate the safety and efficacy of intravenous to oral lefamulin in patients with community acquired bacterial pneumonia. This is a key treatment as CABP is the leading cause of infectious death in the United States.




The data comes from the first of 2 pivotal Phase 3 clinical trials surrounding lefamulin. According to the press release offered by Nabriva Therapeutics, the trial met the United States Food and Drug Administration primary endpoint of non-inferiority when compared to moxifloxacin with or without adjunctive liezolid for early clinical response assesed 72 to 120 hours following initiation of therapy in the intent to treat population. The company announced that ECR rates were 87.3% for lefamulin and 90.2% for moxifloxacin with or without linezolid. In a statement, Dr. Colin Broom, CEO at NBRV, had the following to offer:

These Phase 3 data provide strong evidence of the potential of lefamulin to treat adults with CABP and provide an alternative to a current gold standard treatment regimen… Due to lefamulin’s flexible dose and targeted spectrum of activity against the pathogens most commonly associated with CABP, including multidrug-resistant strains, we believe that lefamulin is well suited to be a first-line empiric monotherapy. I am extremely proud and appreciative of the Nabriva Therapeutics team that has advanced lefamulin, which has the potential to be the first in a new class of antibiotics for CABP in more than 15 years, from initial discovery in our labs to this important milestone. We continue to execute on our second pivotal trial evaluating oral lefamulin for the treatment of CABP, with enrollment expected to complete in the fourth quarter of 2017 and topline results anticipated in the spring of 2018.”

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on NAVB. In particular, we’re interested in following the continued development of lefamulin as the treatment seems to be an overwhelmingly promising new option for treating CABP. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 899
Clovis Oncology CLVS Stock News

Clovis Oncology Inc (NASDAQ: CLVS) is having an interesting start to the trading session this morning. While we have seen quite a bit of up and down this morning, the stock is currently spiking as the result of a takeover rumor. Of course, if a takeover were to happen, it would lead to an incredible return of value for investors. As a result, the rumor is causing quite a bit of excitement. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. At the moment (10:10), CLVS is trading at $71.03 per share after a gain of $1.57 per share (2.26%) thus far today.





CLVS Gains On Takeover Rumors

As mentioned above, Clovis Oncology is having an incredibly strong start to the trading session this morning as rumors surface surrounding the company. According to the rumors, a takeover offer has been made by Eli Lilly & Co. (NYSE: LLY). The rumors suggest that LLY has put an offer in to take CLVS over at a price of $110 per share, representing an overwhelmingly strong premium, given the current price on the stock.




While this rumor is indeed exciting, it’s important to remember that rumors, especially takeover rumors, are nothing new to the market. In fact, we see them just about every day. Nonetheless, market rumors are just like any other rumor. They are largely invalid. While this particular rumor has quite a bit more detail than most others in the market and the idea of a LLY takeover of CLVS is very practical, there has been no confirmation from either side of the fence. As a result, it’s important that if you do trade based on this rumor, you do so with caution.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will keep a close eye on CLVS and LLY. In particular, we’re interested in learning if the rumored takeover offer is valid. Of course, if the rumors are correct and CLVS does indeed take the offer, we’ll see a strong return of value to investors. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Himax Technologies HIMX Stock News

Himax Technologies, Inc. (ADR) (NASDAQ: HIMX) is having an overwhelmingly strong start to the trading session this morning. While the company hasn’t released any news this morning or over the weekend, there are rumors surfacing that we believe to be the cause for the gains. As is normally the case, our partners at Trade Ideas were the first to alert us to the movement. At the moment (9:48), HIMX is trading at $10.89 per share after a gain of $0.34 per share (3.18%) thus far today.





HIMX Gains On Rumors

As mentioned above, Himax Technologies is having an overwhelmingly strong start to the trading session today as rumors surface surrounding the company. The rumors suggest that the company has been awarded a new contract. However, they are also overwhelmingly vague. While there is an insinuation that a new contract has been awarded, there is no news with regard to who awarded the company the contract, what the contract is for, nor how much revenue the contract will drive.




Any time we see rumors in the market, as is the case with HIMX at the moment, we feel it’s important to remind investors that this is nothing new. The truth of the matter is that rumors are a daily occurrence in the stock market. Like most rumors, market rumors tend to lack validity. In this particular case, we urge those who plan on making moves based on this rumor to use caution. At the end of the day, it is overwhelmingly vague and seemingly impossible to track to the source. These tend to be the trademarks of false rumors designed to drive movement in the market.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on HIMX. In particular, we’re interested in following the company to see if the rumors of a new contract being awarded are true or not. While we don’t believe the rumor, anything can happen in the market. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 362
Pluristem Therapeutics Inc. PSTI Stock News

Pluristem Therapeutics Inc. (NASDAQ: PSTI) is off to an incredibly strong start to the trading session this morning after the company announced that the FDA has granted Fast Track Designations to one of their pipeline drugs. As we have grown to expect, the news was overwhelmingly exciting to investors who are pushing the stock toward the top. Of course, our friends at Trade Ideas were the first to alert us to the gains. At the moment (9:30), PSTI is trading at $1.58 per share after a gain of $0.24 per share or 17.99% thus far today.





PSTI Gains On Fast Track Designation

As mentioned above, Pluristem Therapeutics is having an overwhelmingly strong start to the trading session today after the company announced some key FDA news. In a press release offered early this morning, the company announced that the United States Food and Drug Administration has granted Fast Track Designation surrounding PLX-PAD cells for the treatmnet of Critical Limb Ischema in patients that are ineligible for ravascularization.




As a result of the Fast Track Designation, PSTI will enjoy an expedited review process surrounding PLX-PAD. This will ultimately help the company bring the treatment to market at a faster rate should it qualify to be commercialized in the United States. In a statement, Zami Aberman, Chairman and Co-CEO at PSTI, had the following to offer:

We are extremely pleased with the FDA’s decision to grant Fast Track Designation to PLX-PAD in the treatment of CLI. Up to 40% of patients with CLI are ineligible for revascularization and are at high risk of amputation and death within the first year of diagnosis. This disease takes a heavy toll on patients and their families, while the cost of treating CLI in the U.S. alone is estimated at over $25 billion per year. We are working tirelessly to provide a cell therapy that will address this severe unmet medical need.”

The above statement was followed up by Yaky Yanay, President and Co-CEO at PSTI, with the following:

Regulators in some of the largest healthcare markets in the world are now in alignment regarding the need for accelerated approval pathways for our cell therapy product in the treatment of CLI. Programs like the Fast Track Designation offer real hope for patients battling this disease and we look forward to accelerating the path to market for PLX-PAD.”

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on PSTI. In particular, we’re interested in following the ongoing development surrounding PLX-PAD as well as other treatments in the company’s impressive pipeline. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 337
Pain Therapeutics Inc PTIE Stock News

Pain Therapeutics, Inc. (NASDAQ: PTIE) is having an overwhelmingly strong start to the trading session this morning, and for good reason. The company announced that it has been awarded a key grant which will help to fund further development of a lead pipeline drug. Of course, this led to excitement among investors, sending the stock toward the top. As is almost always the case, our friends at Trade Ideas were the first to alert us to the gains. At the moment (8:52), PTIE is trading at $4.34 per share after a gain of $0.45 per share or 11.57% thus far today.





PTIE Gains On Grant

As mentioned above, Pain Therapeutics is having an incredibly strong start to the trading session this morning after the company announced that it has been awarded a grant. The grant, designed to help fund further research and development was provided by the National Institute on Drug Abuse, or NIDA.

Through the grant, PTIE will receive approximately $2.2 million in funds which will help further the development of FENROCKTM, which is a treatment candidate for severe pain. The treatment is a transdermal patch that delivers fentanyl to manage pain. However, the treatment also includes novel abuse-deterrent technology.




The grant provided by NIDA is based on technical-milestones and will help PTIE immediately move forward with the continued development of FENROCK. The grant was the result of an in-depth evaluation of the company’s technology for both scientific and technical merit.

In a statement, Remi Barbier, President and CEO at Pain Therapeutics, had the following to offer:

We are grateful for NIDA’s scientific and financial support for FENROCK… This grant underscores the urgent need to better address the abuse potential of currently marketed fentanyl patches.”

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on PTIE. In particular, we’ll continue to watch the company’s work with regard to the development of FENROCK as well as other key pipeline drugs. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 406
Green Spirit Industries GSRX Stock News

Green Spirit Industries Inc (OTCMKTS: GSRX) made a key announcement yesterday surrounding their plans of constructing 5 medical marijuana dispensaries in Puerto Rico. In the update, the company informed investors that current construction projects surrounding these goals remain on track. Here’s what we saw…





GSRX Announces That Construction Remains On Track

As mentioned above, Green Spirit Industries made a key announcement yesterday surrounding their goal of building 5 medical marijuana dispensaries in Puerto Rico. The announcement came through the company’s wholly-owned subsidiary known as Project 1493, LLC. According to the announcmeent construction of three of its planned medical cannabis dispensary locations in Puerto Rico remains on track following Hurricane Irma. All three of these dispensaries are still expected to open in the fourth quarter of this year. Currently, 3 of the dispensaries are under construction and GSRX plans on starting construction of the fourth dispensary in Isla Verda as well as the fifth in Fajardo in the coming weeks. In a statement, Les Ball, CEO at GSRX, had the following to offer…




We are grateful that this island and its people were spared the worst of Irma, and our prayers are with other members of our Caribbean island family who suffered tragic loss of life and monumental destruction… We remain united with our neighbors here, and are committed to bringing our products and services to those patients in Puerto Rico who are awaiting the opening of our dispensaries, as quickly as possible. Our proposed locations are undamaged, and construction has resumed.

We encourage anyone who is able to lend assistance to the people of those Carribean islands that were hit the hardest to do so. News reports are showing how Puerto Rico is welcoming evacuees from neighboring St. Thomas and St. Marteen, while private citizens here have been taking much-needed supplies by personal watercraft from Fajardo to St. Thomas, and returning with boatloads of evacuees. And Richard Branson, whose own Necker Island was left in shambles, is mobilizing to help with relief on neighboring Carribean islands. Together, we will all rebound and recover from Irma, and will emerge stronger than ever.”

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to watch GSRX incredibly closely. In particular, we’re interested in following the company’s work with regard to their plans of constructing the dispensaries in Puerto Rico and are excited to see the result as they come. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 494
Advanced Medical Isotope Corporation ADMD Stock News

Advanced Medical Isotope Corp. (OTCMKTS: ADMD) released some big news yesterday! The company announced that it has had its first discussions with private animal consortiums to utilize RadioGelTM. This is a huge step in the right direction. Here’s what’s happening:





ADMD Holds First Talks With Private Animal Consortiums

As mentioned above, Advanced Medical Isotope made a major leap with an announcement yesterday surrounding their goal of bringing RadioGel to market for the treatment of skin cancer. The company announced yesterday that it has held its first discussions with private animal consortiums in order to prove safety and effectiveness of the product through testing at four university veterinary hospitals.




By taking advantage of access to private veterinary clinics, the company will be able to form business arrangements with large consortiums of private clinics in a cost-effective way. The company has had conversations with Veterinary Cancer Group and with VCA Inc. with the goal of gaining firsthand information on the steps required to market RadioGel in the commercial sector. With 55 veterinary centers that feed into 3 specialty clinics. VCA has 820 clinics in the United States and Canada with 25 specialty treatment centers.

According to the company’s press release, both consortiums have expressed a strong opinion with regard to the importance of learning from testing that the company is sponsoring at university veterinary centers. They have also encouraged ADMD to publish the results in a scientific journal. In fact, VCG expressed interest in teaming up with the universities by conducting some of the testing within their own facilities.

With such interest in the veterinary space, ADMD will likely have all it needs in order to move through the non-human testing phase surrounding this potentially game-changing treatment. Ultimately, this brings them one step closer to testing in humans, and their ultimate goal of bringing the treatment to the regulatory approval under the skin cancer indication.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on ADMD. I particular, we’re interested in following the ongoing efforts surrounding RadioGel and excited to see where this treatment goes as it continues through development. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Top Ships Inc TOPS Stock News

Top Ships Inc (NASDAQ: TOPS) is having an incredibly strong start to the trading session this morning, and for good reason. The company announced that it has entered into a timed charter and loan agreement. Of course, this led to excitement among investors, leading to gains in the market. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. At the moment (10:17), TOPS is trading at $0.66 per share after a gain of $0.28 per share or 74.50% thus far today.





TOPS Gains On Charter And Loan Agreement

As mentioned above, Top Ships is having an incredibly strong day in the market today after announcing that it has entered into a partnership and loan agreement. The agreement surrounds a ship that is expected to be delivered by Hyundai in the third quarter of 2018. At this time, M/T Eco Palm Desert will enter into a time charter employment with Central Ship Chartering Inc, a related party. The agreement will have a term of 3 years. Following the initial 3 year period, the charter has the option to extend the firm employment period by an additional two years. It is expected that gross revenue surrounding the time charter will reach up to $27.5 million. This figure includes optional periods.




On top of the time charter agreement, the company also entered into a bank loan facility with a European bank for the financing of Eco Palm Desert. The agreement will give the company $23.5 million to work with. In a statement, Evangelos Pistolis, President and CEO at TOPS, had the following to offer…

The total gross revenue backlog for the fixed charter period of all of the Company’s operating fleet stands at about $106 million and when adding the 50% of our joint venture vessels it increases to about $122 million, with cashflow visibility reaching into 2021. Our business strategy continues to be focused on further expanding our fleet as it is important that we can achieve a certain critical mass in terms of fleet size with an aim to maximize our operational efficiencies and synergies.”

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on TOPS. In particular, we’re interested in following the news surrounding the vessel that’s coming soon and keeping an eye on the operation surrounding the vessels that are currently in use. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 433
Halozyme Therapeutics, Inc. HALO Stock News

Halozyme Therapeutics, Inc. (NASDAQ: HALO) is up big in the market early on this morning, and for good reason. An announcement was made with regard to a key partnership, leading to excitement among investors and sending the stock toward the top. As is almost always the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (9:33), HALO is trading at $15.94 per share after a gain of $2.76 per share or 20.93% thus far today.





HALO Gains On Partnership News

As mentioned above, Halozyme Therapeutics is having an overwhelmingly strong start to the trading session this morning after the company announced a couple key partnerships. The company announced early this morning that it would be licensing its drug delivery technology to both Bristol-Myers Squibb (BMY) and Swiss pharmaceutical company, Roche in two separate collaborations.




As a result of the licensing agreements, HALO raised its 2017 revenue forecasts. The company now expects that revenue for the full year will come in between $245 million and $260 million. That’s a big jump from previous guidance of $115 million to $130 million.

With regard to the licensing agreements, HALO will be bringing in $135 million in upfront payments. $105 of which will come from BMY while the other $30 million will come from Roche. The technology licensed is the Enhanze technology, which is designed to help speed up the administration of injectable drugs.

Moving forward, Halozyme could end up bringing in an additional $160 million from both deals combined. These funds will be associated with milestones including development, regulatory and sales-based goals.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on HALO. In particular, we’re interested in watching the continued work surrounding Enhanze and excited to see the result of the collaborations mentioned above. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 1352
Atossa Genetics Inc ATOS Stock News

Atossa Genetics Inc (NASDAQ: ATOS) is having an incredibly strong time in the market in the pre-market hours this morning. Through a search on various PR services, the company’s website, and search engines, we were unable to find anything new. However, we were able to find a rumor that broke early this week that seems to be the cause of gains considering comments on message boards around the web. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (8:03), ATOS is trading at $0.78 per share after a gain of $0.09 per share or 12.39% thus far today.





ATOS Continues Upward On Rumors

As mentioned above, Atossa Genetics is having a pretty strong start in the pre-market hours this morning as investors seem to be looking back to rumors that hit the wire early this week. The rumors suggest that Merck & Co has been in meetings to discuss a potential partnership surrounding the pipeline drug Endoxifen following a successful Phase 1 clinical trial. According to unnamed sources, Merck is very positive surrounding the potential partnership as it would add another dimension to the company’s current breast cancer drug profile. ATOS and MRK supposedly met on Monday at first and it is expected that more meetings will be taking place today and tomorrow.




As is always the case when we talk about rumors, it’s important that I mention that rumors happen all the time in the market. Very few of these rumors hold any validity. While this particular rumor comes with quite a bit of detail and seems to be pretty valid, it’s important to keep in mind that it is still a rumor, and therefore, it may be false. So, if you’re going to trade on this news, please be sure to do so with caution.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on ATOS. In particular, we’re interested in following the story to see if MRK does indeed sign a partnership agreement with the company. Nonetheless, we’ll continue to follow the news and bring it to you as it breaks.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Thought Leader Discussions

Gevo, Inc. GEVO Stock News

0 6573
Gevo, Inc. (NASDAQ: GEVO) Before we get into this interview, I'd like to extend a special thanks to my friend Joey who both set up the...